

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Boill Healthcare Holdings Limited**

### **保集健康控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 01246)**

## **PROFIT WARNING**

This announcement is made by Boill Healthcare Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that the Group is expected to record an approximately 60% increase in consolidated net loss for the six months ended 30 September 2018 (the “**Period**”) as compared to the six months ended 30 September 2017. Such expected substantial increase in consolidated net loss for the Period was mainly due to the following:

- (i) There is a net loss incurred by the foundation piling business in the Period and it was mainly attributable to the discounts offered for the tendered projects to deal with the intense competition with other subcontractors in the tender, which led to an approximately 70% drop in the revenue in this segment. However, the other costs (including depreciation and salaries) did not drop in line with the revenue;
- (ii) The construction of the project relating to Shanghai Jin Sheng Long Real Estate Co., Ltd is still under construction and no revenue has been recognised but the cost incurred for daily operation was not less than HK\$12.1 million for the Period (2017: approximately HK\$2.5 million);
- (iii) No significant fair value gains on investment properties under construction were derived for the Period (2017: approximately HK\$17.1 million); and
- (iv) No significant fair value gains on equity investment were derived for the Period (2017: approximately HK\$31.2 million).

The Company is still in the process of finalising the interim results of the Group for the Period. The information contained in this announcement is only based on preliminary assessment made by the Board with reference to the unaudited consolidated management accounts of the Group for the Period, which are subject to adjustments as appropriate and final review by the Company and its auditor.

The Shareholders and potential investors are advised to read carefully the interim results announcement of the Group for the Period for further details, which is expected to be published on 30 November 2018.

**The Shareholders and potential investors are advised to exercise caution when dealing securities of the Company.**

By order of the Board  
**Boill Healthcare Holdings Limited**  
**Dai Dong Xing**  
*Executive Director and Chairman*

Hong Kong, 23 November 2018

*As at the date of this announcement, the Company has (i) four executive Directors, namely Mr. Dai Dong Xing, Mr. Mock Wai Yin, Dr. Wong Yun Kuen and Mr. Zhang Sheng Hai; (ii) one non-executive Director, namely Mr. Chui Kwong Kau; and (iii) three independent non-executive Directors, namely Mr. Chan Chi Keung Billy, Mr. Xu Liang Wei and Mr. Wang Zhe.*

*In the case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.*